Is Avatrombopag/Suxin a hormonal drug?

Avatrombopag/Avatrombopag is an oral drug mainly used to treat idiopathic thrombocytopenia (ITP). Its mechanism of action is different from that of hormonal drugs. Avatrombopag is a thrombopoietin receptor agonist that can stimulate the proliferation and differentiation of megakaryocytes in the bone marrow, thereby increasing platelet production. This mechanism allows it to show good efficacy in increasing patients' platelet counts.

Avatrombopag, formerly known asAKR-501 and YM477, is an orally administered small molecule thrombopoietin (TPO) receptor agonist, not a hormonal drug, that mimics the biological effects of TPO in vitro and in vivo. Avatrombopag binds to a unique transmembrane site on the TPO receptor and does not block native TPO binding. While hormonal drugs usually work by affecting the immune system or directly acting on the inflammatory response, avatrombopag specifically targets platelet production. Although in some cases, doctors may use hormonal drugs and avatrombopag together to enhance the effect of treatment, the two are pharmacologically different.

Hormonal drugs such as corticosteroids treat ITP mainly by suppressing the immune responseAvatrombopag directly promotes platelet production. In vitro studies have shown that avatrombopag stimulates the proliferation of human c-Mpl-Ba/F3 cells [half maximum effective concentration (EC50) 3·3±0·2nmol/l] and promotes the formation of megakaryocyte colonies in human CD34+ cells (EC50 24·8±7·8nmol/l). The effects of avatrombopag and TPO on megakaryopoiesis are additive. Furthermore, oral administration of avatrombopag increased human platelet counts in a dose-response manner in non-obese diabetic/severe combined immunodeficient mice transplanted with human hematopoietic stem cells. These preclinical data suggest that avatrombopag has therapeutic potential in treating thrombocytopenia of various etiologies, including immune thrombocytopenia (ITP), chronic liver disease (CLD), and chemotherapy-induced thrombocytopenia (CIT).